The Enterprise Value as of December 2024 (TTM) for Enanta Pharmaceuticals, Inc. (ENTA) is 147.52M

According to Enanta Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 147.52M. This represents a change of -50.66% compared to the average of 299.01M of the last 4 quarters.

Enanta Pharmaceuticals, Inc. (ENTA) Historical Enterprise Value (quarterly & annually)

How has ENTA Enterprise Value performed in the past?

The mean historical Enterprise Value of Enanta Pharmaceuticals, Inc. over the last ten years is 815.79M. The current 147.52M Enterprise Value has changed 1.71% with respect to the historical average. Over the past ten years (40 quarters), ENTA's Enterprise Value was at its highest in in the June 2018 quarter at 2.20B. The Enterprise Value was at its lowest in in the September 2024 quarter at 18.23M.

Enanta Pharmaceuticals, Inc. (ENTA) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of Enanta Pharmaceuticals, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Enanta Pharmaceuticals, Inc. (ENTA) Average Enterprise Value

How has ENTA Enterprise Value performed in the past?

The current Enterprise Value of Enanta Pharmaceuticals, Inc. (ENTA) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

Enanta Pharmaceuticals, Inc. (ENTA) Enterprise Value vs. Peers

How is ENTA’s Enterprise Value compared to its peers?

Enanta Pharmaceuticals, Inc.’s Enterprise Value is less than Monte Rosa Therapeutics, Inc. (351.25M), less than Design Therapeutics, Inc. (331.74M), greater than Werewolf Therapeutics, Inc. (-17421672.00), greater than Ikena Oncology, Inc. (37.04M), less than Stoke Therapeutics, Inc. (451.87M), less than Crinetics Pharmaceuticals, Inc. (4.74B), greater than Inhibrx Biosciences, Inc. (15.26M), less than Merus N.V. (2.47B), greater than Lyell Immunopharma, Inc. (130.21M), greater than Kronos Bio, Inc. (8.15M), greater than Century Therapeutics, Inc. (89.16M), less than Edgewise Therapeutics, Inc. (2.76B), less than C4 Therapeutics, Inc. (280.63M), less than Mineralys Therapeutics, Inc. (539.76M), less than Cullinan Oncology, Inc. (614.81M), greater than Theseus Pharmaceuticals, Inc. (138.26M), less than Revolution Medicines, Inc. (7.98B),

Build a custom stock screener for Enanta Pharmaceuticals, Inc. (ENTA) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Enanta Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Enanta Pharmaceuticals, Inc. (ENTA) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Enanta Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.